[The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].

Silvia Muccioli, Carlotta Giglio,Gianmarco Annibali, Eleonora Cerutti, Stefania Civera, Rebecca Casati, Fabrizio Delnevo, Catia De Rosa,Sergio Bongioanni,Marzia Colopi,Nicola Gandolfo,Tiziana Aranzulla,Francesca Bianchi,Alessandro Blandino,Massimo Borrione,Stefano Grossi,Stefania Luceri,Barbara Mabritto, Chiara Carceri,Emanuele Meliga,Iris Parrini,Alfredo Pizzuti,Innocenzo Scrocca,Andrea Sibona Masi,Antonino Tomasello, Annalisa Gasco,Giuseppe Musumeci

Giornale italiano di cardiologia (2006)（2022）

引用 1|浏览4

暂无评分

摘要

Prescription of intensive lipid-lowering therapy after acute coronary syndrome, eventually with introduction of PCSK9i during hospitalization or at discharge, leads to attainment of guideline-recommended goals for all patients, with a low incidence of adverse events and optimal compliance.

查看译文

关键词

acute coronary syndrome,coronary syndrome,lipid-lowering

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要